A new ELISA for determination of potency in snake antivenoms

Autores
Rial, A.; Morais, V.; Rossi, S.; Massaldi, Hugo Alberto
Año de publicación
2006
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Abstract A competitive ELISA for potency determination of bothropic equine antivenom was developed and compared to the conventional in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.0)2 fragment.
Fil: Rial, A.. Universidad de la República; Uruguay
Fil: Morais, V.. Universidad de la República; Uruguay
Fil: Rossi, S.. Universidad de la República; Uruguay
Fil: Massaldi, Hugo Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de la República; Uruguay
Materia
ANTIVENOM
ELISA
ED50
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/248323

id CONICETDig_3f51b2f30943b00e9af3356af0141a86
oai_identifier_str oai:ri.conicet.gov.ar:11336/248323
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling A new ELISA for determination of potency in snake antivenomsRial, A.Morais, V.Rossi, S.Massaldi, Hugo AlbertoANTIVENOMELISAED50https://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Abstract A competitive ELISA for potency determination of bothropic equine antivenom was developed and compared to the conventional in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.0)2 fragment.Fil: Rial, A.. Universidad de la República; UruguayFil: Morais, V.. Universidad de la República; UruguayFil: Rossi, S.. Universidad de la República; UruguayFil: Massaldi, Hugo Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de la República; UruguayPergamon-Elsevier Science Ltd2006-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/248323Rial, A.; Morais, V.; Rossi, S.; Massaldi, Hugo Alberto; A new ELISA for determination of potency in snake antivenoms; Pergamon-Elsevier Science Ltd; Toxicon; 48; 4; 9-2006; 462-4660041-0101CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0041010106002352info:eu-repo/semantics/altIdentifier/doi/10.1016/j.toxicon.2006.07.004info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:41:29Zoai:ri.conicet.gov.ar:11336/248323instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:41:29.714CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv A new ELISA for determination of potency in snake antivenoms
title A new ELISA for determination of potency in snake antivenoms
spellingShingle A new ELISA for determination of potency in snake antivenoms
Rial, A.
ANTIVENOM
ELISA
ED50
title_short A new ELISA for determination of potency in snake antivenoms
title_full A new ELISA for determination of potency in snake antivenoms
title_fullStr A new ELISA for determination of potency in snake antivenoms
title_full_unstemmed A new ELISA for determination of potency in snake antivenoms
title_sort A new ELISA for determination of potency in snake antivenoms
dc.creator.none.fl_str_mv Rial, A.
Morais, V.
Rossi, S.
Massaldi, Hugo Alberto
author Rial, A.
author_facet Rial, A.
Morais, V.
Rossi, S.
Massaldi, Hugo Alberto
author_role author
author2 Morais, V.
Rossi, S.
Massaldi, Hugo Alberto
author2_role author
author
author
dc.subject.none.fl_str_mv ANTIVENOM
ELISA
ED50
topic ANTIVENOM
ELISA
ED50
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.11
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Abstract A competitive ELISA for potency determination of bothropic equine antivenom was developed and compared to the conventional in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.0)2 fragment.
Fil: Rial, A.. Universidad de la República; Uruguay
Fil: Morais, V.. Universidad de la República; Uruguay
Fil: Rossi, S.. Universidad de la República; Uruguay
Fil: Massaldi, Hugo Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de la República; Uruguay
description Abstract A competitive ELISA for potency determination of bothropic equine antivenom was developed and compared to the conventional in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo ED50 assay, with the aim of partially substituting the in vivo assay in the monitoring of antivenom immunoglobulin levels. On this purpose, blood samples were taken at different times during and after the immunization protocol of the lot of horses used for production of snake antivenom at the Instituto de Higiene, Uruguay. Both the competitive ELISA and the ED50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 assay were performed on those samples. In addition, a group of five commercial pepsindigested antivenoms were tested by both methods. A significant (Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.Po0.001) correlation (Pearson’s r ¼ 0.957) was found between the ELISA titres and the corresponding ED50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.50 values, indicating that the in vitro test can estimate the neutralizing antibody capacity of the sera as well as the in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.in vivo assay. By means of this new ELISA, it was found that the immunized animals maintained good venom antibody titres, in the order of 20–50% of the maximum achieved, even 10 month after the end of the immunization schedule. The main advantage of our ELISA design is its ability to correctly estimate the neutralization capacity of crude hyperimmune plasma and antivenom sera independently of their antibody composition in terms of whole IgG or F(ab0)2 fragment.0)2 fragment.
publishDate 2006
dc.date.none.fl_str_mv 2006-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/248323
Rial, A.; Morais, V.; Rossi, S.; Massaldi, Hugo Alberto; A new ELISA for determination of potency in snake antivenoms; Pergamon-Elsevier Science Ltd; Toxicon; 48; 4; 9-2006; 462-466
0041-0101
CONICET Digital
CONICET
url http://hdl.handle.net/11336/248323
identifier_str_mv Rial, A.; Morais, V.; Rossi, S.; Massaldi, Hugo Alberto; A new ELISA for determination of potency in snake antivenoms; Pergamon-Elsevier Science Ltd; Toxicon; 48; 4; 9-2006; 462-466
0041-0101
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0041010106002352
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.toxicon.2006.07.004
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613310260969472
score 13.070432